Literature DB >> 8256793

Hormone replacement therapy for prevention and treatment of osteoporosis.

R Lindsay1.   

Abstract

Estrogen therapy is clearly effective in the prevention and treatment of osteoporosis. Several estrogens and routes of administration are available. A progestin is required to protect the endometrium if the patient has a uterus. The duration of treatment required is unknown but probably is > or = 10 years for prevention and may be life-long, which is the requirement for patients with established disease. A regimen of patient monitoring can be easily established and must become routine for all patients on long-term treatment.

Entities:  

Mesh:

Year:  1993        PMID: 8256793     DOI: 10.1016/0002-9343(93)90380-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  R H Foster; J A Balfour
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene.

Authors:  A T Bäumer; S Wassmann; K Ahlbory; K Strehlow; C Müller; H Sauer; M Böhm; G Nickenig
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 3.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Molecular Aspects of Bone Resorption in β-Thalassemia Major.

Authors:  Najmaldin Saki; Saeid Abroun; Fatemeh Salari; Fakher Rahim; Mohammad Shahjahani; Mohammadi-Asl Javad
Journal:  Cell J       Date:  2015-07-11       Impact factor: 2.479

5.  Changes in magnetic resonance mammography due to hormone replacement therapy.

Authors:  Stefan O R Pfleiderer; Steffen Sachse; Dieter Sauner; Christiane Marx; Ansgar Malich; Susanne Wurdinger; Werner A Kaiser
Journal:  Breast Cancer Res       Date:  2004-03-16       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.